The company's lead compound, NVG-291, has shown promise for both spinal cord injury and multiple sclerosis, with Phase 1 human clinical trials initiated on healthy subjects in early 2020 and an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. Additionally, the company plans to commence a Phase 2 multiple sclerosis clinical trial in early 2021. NervGen operates in a single segment, focusing on research and development of pharmaceutical drugs, and is publicly traded on the TSX-V and OTCQX. NVG-291 is an experimental drug administered by injection under the skin, which promotes nervous system repair and enhances recovery of functions such as walking, bladder control, vision, and memory in animal studies. The company plans to study the effectiveness and safety of NVG-291 in people with spinal cord injury, Alzheimer's disease, and multiple sclerosis after completing Phase 1 clinical trials.